Acelyrin (NASDAQ:SLRN – Get Free Report) is projected to issue its quarterly earnings data before the market opens on ...

Drug development company Acelyrin Inc. recently saw a modest increase in its stock price after announcing the adoption of a ...

Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated ...

Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 ...

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

After hours: 21 March at 5:07:45 pm GMT-4 Loading Chart for SLRN ...